This Beaten-Down Stock Just Posted Record Revenue. Is It Finally Time to Buy?

• Tilray's latest fiscal results were reasonably strong.

• The institution could person a ample marketplace accidental successful the U.S.

• However, Tilray inactive faces important challenges.

• 10 stocks we similar amended than Tilray Brands ›

Is Tilray Brands (NASDAQ: TLRY) yet turning things around? After unspeakable performances during the past 5 years -- erstwhile the concern mislaid much than 90% of its marketplace worth -- the institution has had beardown momentum successful the past six months.

Much of that was owed to affirmative regulatory developments successful the U.S. cannabis market, but Tilray's astir caller quarterly update was besides good received by the market, with the company's shares rising connected the heels of its net release. Can the banal proceed moving successful the close direction?

On Jan. 8, Tilray reported its fiscal results for the 2nd 4th of its fiscal twelvemonth 2026 (ended Nov. 30). Among different things, the institution noted that its $218 cardinal successful gross during the play was a grounds for the 4th and came successful good up of mean expert estimates.

That sounds impressive, but it's important to look astatine the details. Note that Tilray's apical enactment lone grew by 3% twelvemonth implicit year. That's a batch little impressive.

Looking down astatine the remainder of the company's income statement, determination are adjacent much mixed results. For instance, gross borderline declined to 26% from 29%, adjacent though Tilray reported a narrower nett nonaccomplishment of $43.5 million, compared to the $85.3 cardinal nonaccomplishment successful the prior-year quarter.

Tilray's results were beauteous decent, particularly by the standards of the struggling cannabis industry. However, tin the institution support improving?

Some investors are excited astir Tilray's caller marketplace accidental successful the U.S. Last year, President Donald Trump signed an enforcement bid that reclassified cannabis arsenic a Schedule 3 substance (it was antecedently successful Schedule 1). This alteration volition person respective ramifications, including:

• Easier entree to fiscal services for cannabis companies that run successful the U.S.

• More aesculapian probe into marijuana (Schedule 3 drugs, dissimilar Schedule 1, are legally recognized arsenic having imaginable aesculapian benefits)

• The quality to deduct mean concern expenses

Following these developments, Tilray is looking to grow its aesculapian cannabis operations successful the U.S. The institution launched Tilray Medical USA aft Trump's enforcement order.

This inaugural could assistance the institution grow its portfolio of aesculapian cannabis products successful the state portion partnering with assorted players successful the aesculapian tract to scope a broader excavation of patients. That was overmuch harder before, fixed that cannabis wasn't recognized arsenic having immoderate imaginable aesculapian payment earlier rescheduling.